CLINICAL TRIAL PATIENT TECHNOLOGY INSIGHTS
-
Clinical Research Has System Sprawl Problem
Disconnected systems are strangling clinical trials. Here’s what’s causing the sprawl, why it keeps getting worse, and what needs to change.
-
How Clinical Trial Sites Must Adapt To The Predictive Analytics Era
Clinical trial sites are now measured, ranked, and selected by predictive models. Learn how to perform and compete in this data-driven new era.
ECOA RESOURCES
-
Configurable alarms appear as banner alerts on subjects’ devices, while email notifications help sites monitor potential non-compliance and respond to newly uploaded symptom severity data.
-
Regulators now prioritize fit-for-purpose data over legacy instrument brand names. Modernizing your assessment strategy reduces licensing delays and improves trial startup speed and efficiency.
-
Empower your study participants with IQVIA eCOA’s tailored user experiences, flexible event triggers for clinicians, comprehensive training resources, and 24/7 support for seamless study management.
ECONSENT RESOURCES
-
As much as eConsent helps staff, participants are also likely to prefer it over traditional paper methods. Explore the benefits of eConsent and some strategic steps sites can take right now to adopt the process.
-
Participant-focused eClinical technologies offer significant potential to decrease paper-based processes and improve end-user experiences in collecting patient-reported outcomes (PRO) and informed consent, but many users continue to experience rigid technology, complicated hardware provisioning processes, and clunky implementations that leave sponsors, CROs and sites questioning the value.
-
IQVIA One Home for Sites is a platform that serves as a neutral aggregator, connector, and communicator of the key systems and tasks a clinical research site needs to perform across all the trials it is conducting.
EPRO RESOURCES
-
Participant-focused eClinical technologies offer significant potential to decrease paper-based processes and improve end-user experiences in collecting patient-reported outcomes (PRO) and informed consent, but many users continue to experience rigid technology, complicated hardware provisioning processes, and clunky implementations that leave sponsors, CROs and sites questioning the value.
-
In this blog, explore how the approach to PROs needs to be reconsidered, given increasing regulations and trial scrutiny, the clinical need for patient-reported outcomes, and the ability to drive costs down and move off paper.
-
Utilizing the insights covered in this article can inform the design and implementation of cancer trials, ultimately contributing to improved patient care and treatment outcomes.